Small molecule · developed by Evotec Neurosciences GmbH
EVT 101 is an oral capsule formulation tested in single doses of 8 mg and 15 mg.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00526968 | Phase 1 | Human Volunteers | Completed | EVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Human Volunteers
Updated Nov 15, 2026. Something wrong or missing? Report it on the EVO page.
See EVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EVO catalysts and pipeline →